Relapsing Multiple Sclerosis (RMS) Clinical Trials

• Signed informed consent must be obtained prior to participation in the study

• Male or female patients aged ≥18 years at enrollment

• Diagnosis of MS according to the 2017 revised McDonald criteria (Thompson et al 2018b)

• RMS with active disease as defined by Lublin et al. (2014)

• Max. 1 relapse during the previous year and max. 2 relapses during the previous two years prior to enrollment

• Disability status at enrollment with an EDSS score of 0 to 2.5 (inclusive)

• Planned initiation or initiation within the past 14 days with an approved injectable DMT for MS as routine medical treatment

• Signed informed consent must be obtained prior to participation,

• Male or female patients aged ≥18 years at enrollment,

• Diagnosis of MS according to the 2024 revised McDonald criteria (Montalban et al., 2025),

• RMS with active disease as defined by Lublin et al. (2014) ,

• Max. 1 relapse during the previous year and max. 2 relapses during the previous two years prior to enrollment,

• Disability status at enrollment with an EDSS score of 0 to 3.0 (inclusive),

• Planned initiation or initiation within the past 14 days with an approved injectable or oral DMT for MS as routine medical treatment:

‣ Ofatumumab: only naïve patients or patients previously treated with max. one DMT other than ofatumumab

⁃ IFN-β1, GA, teriflunomide, DMF or DRF: only naïve patients